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lipid storage myopathy with severe cardiac involvement. Patient par-
ents were ﬁrst cousins; a brother died at 3 years of age, during surgery.
They referred that the child had always walked on toes, but he never
presented weakness or difﬁculties in physical activity, compared to
peers. The patient was ﬁrst evaluated when he was 11 years-old and
was reported to walk on toes, with difﬁculty to walk on heels, and toNeutral lipid storage disease
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Triacylglycerol
Lipid droplet
PNPLA2/ATGLMutations in the adipose triglyceride lipase (ATGL), an enzyme that
hydrolyzes fatty acids from triacylglycerol (TG) stored in multiple tis-
sues into cytoplasmic lipid droplets (LDs), causes the autosomal reces-
sive disorder Neutral Lipid Storage Disease with myopathy (NLSDM)
[2]. ATGL protein is coded by PNPLA2 gene. NLSDM patients are mainly
affected by progressive myopathy, cardiomyopathy and hepatomegaly.
Their clinical severity appears to behighly variablewith particular refer-
ence to cardiac involvement [1,6–8]. Cardiomyopathy was reported in
36% of the patients. In some of them, it was lethal (25%), or manifested
with severe heart condition (31%). Patients with cardiac involvement
have adult-onset progressive heart failure, mimicking dilated or hyper-
trophic cardiomyopathy. The analyses of explanted and autopsied
hearts revealed that the defective intracellular hydrolysis of TG results
in congestive heart failure with cardiomyocyte steatosis as well as a
novel type of coronary atherosclerosis with TG-deposit smooth muscle
cells [3–5]. Molecular mechanisms underlying pathophysiology of
heart damage are unknown; moreover, no therapy is available for
NLSDM patients.emistry and Molecular Biology-
melli, 1, 20123 Milan, Italy.
land Ltd. This is an open access articlWe report the case of a 26 year-old male patient affected by neutral
have mild calves hypertrophy and reduced tendon reﬂexes. Blood test
revealed high values of CK (1657 U/L), while total and free carnitine
levels were normal. Electromyography was normal; an effort test re-
vealed excessive increase in lactic acid levels. He underwent a muscle
biopsy that showed abnormal lipid storage. He was diagnosed to suffer
from a lipid storage myopathy and therapy with riboﬂavin was started
with some beneﬁt to the patient.
At 20 years of age, the patient complained of walking difﬁculties and
of exercise intolerance. CK levels remained very high (N2000 U/L). On
neurological evaluation he revealed normal strength, mild fatigability,
reduced tendon reﬂexes, walking on forefoot and impossibility to
walk on heels. He performed squats without limitation, but with pain
at lower limbs. The analysis of plasma free and esteriﬁed carnitine
resulted normal. A muscle CT detected atrophy and fat inﬁltration
of lower limbmuscles. A muscle biopsy revealed numerous vacuoles
(Fig. 1A) positive to lipid staining in most ﬁbers (Fig. 1B). Respirato-
ry chain complexes showed normal activity. Electron microscopy
showed numerous lipid droplets between myoﬁbrils in most ﬁbers,
often causing sarcomere disorganization; while mitochondria were
normal (Fig 1C). A neutral lipid storage myopathy was hypothesized
and molecular analysis of the PNPLA2 gene revealed a homozygous
novel deletion of seven nucleotides in exon 2 (c.41_47delGCTGCGG)
(Fig 1H). The mutated protein was predicted to consist of only four-
teen amino acids (p.G14Afs75X). This mutation was submitted to
GenBank (accession number KU057409).
During most recent years clinical features of the patient have
progressively deteriorated with mild involvement of upper limbs
and worsening of distal lower limb weakness; moreover walking
difﬁculties become more evident. Whole-body MRI detected mild
fatty inﬁltration of bilateral trapezius, deltoid and infraspinatus;
severe fatty degeneration of pelvic girdle muscles, hamstring,e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Histochemical, clinical and molecular characterization of NLSDM patient. Light microscopy of frozen transverse sections of skeletal muscle biopsy stained with Gomori trichrome
(A) and Oil Red O (B) show an increase of lipid droplets; electron microscopy reveals massive line-up of lipid droplets without signs of mitochondrial alteration (C).Whole-body MRI
showing: in (D) mild fatty inﬁltration of trapezius, deltoid and infraspinatus muscles; in (E) the posterior thigh muscles (hamstring, semimembranosus and semitendinosus) more
severely involved than the quadriceps; in (F)severe fatty inﬁltration of leg muscles, with partial saving of anterior and posterior tibialis; and in (G) the diffuse involvement of the
gluteus muscles. Electropherogram of PNPLA2 exon 2 sequence with the c.41_47delGCTGCGG homozygous mutation in patient (H); wild type sequence of exon 2 in a control subject
in (I).
166 Correspondencesemimembranosus and semitendinosus; diffuse fatty inﬁltration of
leg muscles with partial saving of anterior and posterior tibialis
(Fig 1D–G).
The patient has undergone cardiological evaluation at 24 years of
age. Cardiac MRI detected left ventricular dilation with diffused
hypokinesia, moderate–severe reduction of left ventricular systolic
function (ejection fraction FE 36%) and ﬁbrosis of cardiac wall, with-
out fatty inﬁltration (Fig. 2). A CT excluded coronary pathology, and
no innervation defects were seen by myocardial scintigraphy.
Holter-ECG revealed sinus rhythm without arrhythmia or conduc-
tion defects. A cardiopulmonary exercise test showed a severe re-
duction in functional capacity mainly due to cardiogenic and
extraction defect. After those exams, the patient started a therapy
with enalapril 5 mg bid and ivabradine 7.5 mg/die. During the subse-
quent follow up both exercise capacity and echocardiography ejec-
tion fraction improved signiﬁcantly, indeed oxygen consumption
increased from 48% to 57% of the predicted value and a recent
echocardiography, performed a year and a half after starting treat-
ment, conﬁrmed the reduction in left ventricle volume and detected
a recovery of ventricular function (FE 53%). No indication to
implantable-cardioverter-deﬁbrillator (ICD) implantation has been
given by the cardiologist so far.To the best of our knowledge, 44NLSDMpatients have been clinical-
ly and genetically characterized until now [3,6]; about one third of them
presented cardiac myopathy. More than 90% of NLSDM patients (with
cardiac involvement) harbor highly deleterious PNPLA2 mutations,
causing no ATGL protein production or non-functional ATGL truncated
proteins. By contrast, patients with missense mutations – partially pre-
serving lipase activity – have been generally described without cardiac
involvement [8]. The PNPLA2mutation identiﬁed in our patient, deter-
mining total loss of ATGL protein, caused early onset and severe myo-
cardial damage. Noteworthy, the patient showed an improvement of
cardiac function after therapy with enalapril and ivabradine, in spite of
the severe molecular defect. These drugs did not counteract neutral
lipid accumulation and yet determined a signiﬁcant recovery of ventric-
ular function. Informed consent for genetic and clinical analyses were
obtained from the patient. Moreover, written informed consentwas ob-
tained for publication of this Case report and any accompanying images.
It has already been suggested that molecular and functional analysis
of ATGL may improve NLSDM prognosis, paving the way towards per-
sonalized therapy. Nevertheless, intra-familial distinct cardiac pheno-
type has been recently reported in NLSDM [3], underlining that
molecularmechanisms regulating the disease development could be in-
ﬂuenced by other factors in addition to genotype. Since ATGL deﬁciency
Fig. 2. Left ventricle ﬁbrosis detected by cardiovascular magnetic resonance. Contrast-enhanced inversion-recovery gradient-echo images of left ventricle (basal portion, panel A and
middle portion, panel B) in short-axis views, showing subepicardial late gadolinium enhancement of interventricular septum (arrows) and meso-subepicardial late gadolinium
enhancement of anterior-lateral free wall (head arrows). LV = left ventricle.
167Correspondenceis a very rare disease, the international registry for NLSDM has been
established (www.tgcv.org/r/home.html) with the purpose to compare
different clinical phenotypes and elucidate NLSDM pathophysiology.
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